26 September, 2019 – Teva UK Limited welcomes the appointment of Christoph Stoller as President of Medicines for Europe, the pan-European trade association that represents the generic, biosimilar and value added pharmaceutical industries across the continent. Medicines for Europe members supply over 67% of all medicines in Europe, and members’ portfolio cover 80% of therapy areas.1 Christoph is currently General Manager for Teva Germany and Austria, and has taken an active role on the Medicines for Europe Board over the last 5 years.
Christoph has outlined his top priorities for the organization, which include:
- Driving the use of high quality generic, biosimilar and value added medicines to ensure sustainable access to medicines
- Tackling the root causes of medicine shortages
- Innovating in digital healthcare to bring additional benefits to patients and healthcare systems
- Continuing progress industry commitment to reducing environmental impact
Kim Innes, General Manager of Teva UK & Ireland, commented:
“The appointment of Christoph as President of Medicines for Europe is a positive one, not only for Teva but the whole industry. High-quality generic medicines and biosimilars are really vital to the future sustainability of healthcare systems as they drive efficiencies and reduce cost, so it’s great to see Christoph committing to push for sustainable access to medicines. His commitment to tackling the industry-wide issue of medicine shortages across Europe is also welcome.”
About Christoph Stoller
Christoph Stoller is a Senior Vice President of Teva and President of Medicines for Europe.
In his current role as General Manager for Teva´s cluster Germany & Austria he is responsible for Teva´s Generics, OTC and Specialty Medicines businesses and he is Managing Director of all Teva´s legal entities in Germany. Until June 2017 he served as Chief Operating Officer Global Generic Medicines Europe. Christoph has been a member of the Board as well as of the Executive Committee of Medicines for Europe since 2014.
About Medicines for Europe
Medicines for Europe represents the generic, biosimilar and value added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value added medicines. Learn more about Medicines for Europe at www.medicinesforeurope.com
About Teva UK Limited
Our medicines are taken by millions of UK patients, and we are proud to be the largest medicines supplier to the NHS. We supply medicines to treat a wide range of diseases and conditions – from multiple sclerosis, asthma, cancer, migraine and Chronic Obstructive Pulmonary Disease, to pain relief, cholesterol reducers and antibiotics. Our UK headquarters and distribution center is located in Castleford, West Yorkshire. We also have additional offices and facilities in Harlow, Eastbourne, Runcorn and Larne. Learn more about Teva UK at www.tevauk.com and on Twitter @Teva_UK
We are the UK subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), who have been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of thousands of products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more about our global presence at www.tevapharm.com.
UK/CPE/18/0019(1)a
Date of preparation: September 2019